Over the past five years, diabetes-focused medical device specialist DexCom ( DXCM -0.50%) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...
Sotagliflozin was approved by the U.S. Food and Drug Administration in May 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults ...